Literature DB >> 3857619

Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX.

R A McGraw, L M Davis, C M Noyes, R L Lundblad, H R Roberts, J B Graham, D W Stafford.   

Abstract

We have independently isolated and characterized cDNA and genomic clones for the human coagulation factor IX. Sequence analysis in both cases indicates that threonine is encoded by the triplet ACT as the third residue of the activation peptide. This is in agreement with some earlier reports but in disagreement with others that show the alanine triplet GCT at this position. The discrepancy can thus be accounted for by natural variation of a single nucleotide in the normal population. Amino acid sequence analyses of activated factor IX from plasma samples of four individuals yielded two cases of alanine and two cases of threonine at the third position of the activation peptide. In factor IX from pooled plasma and in factor IX from a heterozygous individual, however, both alanine and threonine were found. Taken together, the findings show that a prevalent nondeleterious dimorphism exists in the activation peptide of human coagulation factor IX.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3857619      PMCID: PMC397663          DOI: 10.1073/pnas.82.9.2847

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  The application of 0.1 M quadrol to the microsequence of proteins and the sequence of tryptic peptides.

Authors:  A W Brauer; M N Margolies; E Haber
Journal:  Biochemistry       Date:  1975-07       Impact factor: 3.162

2.  Chromatography of human prothrombin complex or dextran sulphate agarose.

Authors:  D S Pepper; C Prowse
Journal:  Thromb Res       Date:  1977-11       Impact factor: 3.944

3.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

4.  The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent).

Authors:  K Fujikawa; M E Legaz; H Kato; E W Davie
Journal:  Biochemistry       Date:  1974-10-22       Impact factor: 3.162

5.  Structural abnormalities of the vitamin K-dependent clotting factors.

Authors:  H R Roberts; M J Griffith; K M Braunstein; R L Lundblad
Journal:  Prog Clin Biol Res       Date:  1981

6.  A protein sequenator.

Authors:  P Edman; G Begg
Journal:  Eur J Biochem       Date:  1967-03

7.  Activation of human factor IX (Christmas factor).

Authors:  R G Di Scipio; K Kurachi; E W Davie
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

8.  A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S.

Authors:  R G Di Scipio; M A Hermodson; S G Yates; E W Davie
Journal:  Biochemistry       Date:  1977-02-22       Impact factor: 3.162

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Solid-phase synthesis of polynucleotides. III. Synthesis of polynucleotides with defined sequences by the block coupling phosphotriester method.

Authors:  K Miyoshi; T Huang; K Itakura
Journal:  Nucleic Acids Res       Date:  1980-11-25       Impact factor: 16.971

View more
  16 in total

1.  Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins.

Authors:  S G Spitzer; B J Warn-Cramer; C K Kasper; S P Bajaj
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

2.  Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene.

Authors:  D D Koeberl; C D Bottema; R P Ketterling; P J Bridge; D P Lillicrap; S S Sommer
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

3.  Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG.

Authors:  D D Koeberl; C D Bottema; J M Buerstedde; S S Sommer
Journal:  Am J Hum Genet       Date:  1989-09       Impact factor: 11.025

4.  Population genetics of coagulant factor IX: frequencies of two DNA polymorphisms in five ethnic groups.

Authors:  D B Lubahn; S T Lord; J Bosco; J Kirshtein; O J Jeffries; N Parker; C Levtzow; L M Silverman; J B Graham
Journal:  Am J Hum Genet       Date:  1987-06       Impact factor: 11.025

Review 5.  Haemophilia A and haemophilia B: molecular insights.

Authors:  D J Bowen
Journal:  Mol Pathol       Date:  2002-04

6.  Recurrent mutations in the factor IX gene: founder effect or repeat de novo events. Investigation of the German haemophilia B population and review of de novo mutations.

Authors:  O Knobloch; B Zoll; K Zerres; H H Brackmann; K Olek; M Ludwig
Journal:  Hum Genet       Date:  1993-08       Impact factor: 4.132

7.  Hemophilia B (Christmas disease) variants and carrier detection analyzed by DNA probes.

Authors:  M C Poon; D H Chui; M Patterson; D M Starozik; L S Dimnik; D I Hoar
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

8.  Variations among Japanese of the factor IX gene (F9) detected by PCR-denaturing gradient gel electrophoresis.

Authors:  C Satoh; N Takahashi; J Asakawa; K Hiyama; M Kodaira
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

9.  Parental origin of factor IX gene mutations, and their distribution in the gene.

Authors:  M Ludwig; T Grimm; H H Brackmann; K Olek
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

Review 10.  The contribution of DNA analysis to carrier detection and prenatal diagnosis of hemophilia A and B.

Authors:  A H Bröcker-Vriends; E Bakker; H H Kanhai; G J van Ommen; P H Reitsma; J J van de Kamp; E Briët
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.